SCHEDULE: Vanguard Group Divests Oruka Therapeutics Stake

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Oruka Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Oruka Therapeutics Inc. (CUSIP: 687604108).
• The filing indicates The Vanguard Group now beneficially owns 0 shares, representing 0% of the class of Common Stock.
• This change is attributed to an internal realignment at The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by such subsidiaries and/or business divisions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for Oruka Therapeutics Inc. as a major institutional investor has divested its direct beneficial ownership, even if due to internal restructuring.

Negatives

• The Vanguard Group, a major institutional investor, no longer reports beneficial ownership in Oruka Therapeutics Inc., indicating a complete divestment of its direct holdings.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from major players like The Vanguard Group, can signal shifts in investment strategy or portfolio rebalancing. While this filing indicates a procedural change for Vanguard, the complete divestment of direct beneficial ownership in Oruka Therapeutics Inc. could be interpreted by the market as a lack of conviction, even if it's due to internal restructuring.

Stakeholder Impact

• Shareholders: Existing shareholders of Oruka Therapeutics Inc. may view the complete divestment by The Vanguard Group as a negative signal, potentially leading to downward pressure on the stock price.
• Oruka Therapeutics Inc. Management: The company might face questions regarding institutional investor confidence, although the filing attributes the change to Vanguard's internal realignment.

Key Dates

Recommendation

The complete divestment of direct beneficial ownership by a major institutional investor like The Vanguard Group, even if due to internal realignment, typically signals a lack of conviction or a strategic shift away from the issuer. This could lead to negative market sentiment and potential downward pressure on the stock price, warranting a sell recommendation for investors holding Oruka Therapeutics Inc. shares.

Keywords

Oruka Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Divestment, SEC Filing, Common Stock